ABSTRACT BACKGROUND: The novel technology of tissue microarray (TMA) allows rapid and cost-effective analysis of hundreds of markers on the same set of specimens. Limited amount of tissue that could be analyzed and problem of tissue heterogeneity, are the major drawbacks of TMA technique for immunohistochemical characterization of lymphomas. METHODS: In this paper 65 cases of lymphomas were analyzed using TMA with following panel of antibodies: BOB1, Oct2, Bcl2, Bcl6, CD20, CD21, CD23, CD3, CD5, CD10, CD43, CD79a, CD138, Cyclin D1, Ki67, MUM1, Pax5, p53. RESULTS: In 14 patients with diffuse large B-cell lymphoma (DLBCL), 5 were classified as germinative center and 3 as non-germinative center cases according to the Bcl6, CD10, and MUM1 positivity. Other 2 patients were identified as T cell rich B cell lymphoma based on morphology and Oct2 and BOB1 positivity of pleomorphic B lymphocytes. DLBCL with Bcl6 + immunophenotype had better overall survival than Bcl6-cases. All cases of classic mantle cell lymphoma had significantly lower Ki-67 proliferation index than blastoid subtypes. There were 14 cases of chronic lymphocytic leukemia /small cell lymphocytic lymphoma, 6 cases with follicular lymphoma, 5 cases of marginal zone lymphoma, and 7 cases of lymphoplazmacitoid lymphoma. In the indolent lymphoma group, survival of patients with p53 +/-was poorer comparing to p53 -group. CONCLUSION: We conclude that TMA technique is a valuable method in diagnosis and prognosis of lymphomas, which are considered very heterogeneous group of hematological neoplasms.
INTRODUCTION
T he novel technology of tissue microarray (TMA) preparation for high throughput profiling of tumor specimens was originally described in 1998 by Kononen et al. (1) . These authors detailed the preparation of paraffin blocks containing up to 1000 cylindrical, 2 mmdiameter core biopsies from archived paraffin blocks of various tumors and normal tissue specimens. The tissue microarray block can be sectioned for morphologic review as well as for standard immunohistochemistry, 1-or 2-color fluorescence in situ hybridization, or mRNA in situ hybridization on consecutive sections. This novel methodology allows for rapid analysis of hundreds of markers on the same set of specimens: up to 200 sections can be cut from each block.
TMA appear to be particularly useful for immunohistochemical characterization of lymphomas. Combining TMA and immunohistochemistry will enable a rapid and cost-effective screening of marker expression. Furthermore, certain molecular markers in lymphoma correlate with differences in course of disease, e.g., p53 over-expression predicts a worse outcome in patients with B-cell chronic lymphocytic leukemia (B-CLL), certain low-grade lymphomas, and mantle cell lymphoma (MCL) irrespective of the stage of disease (2) . Markers defining disease subsets with a particularly aggressive course may be rapidly identified using TMA. Recently, subgroups of diffuse large B-cell lymphoma (DLBCL) have been defined by cDNA microarray (3) . The validation of these findings at the post-transcriptional level will be greatly enhanced by combining TMA with immunohistochemistry. In a recent paper from 2004 written by Hans and co workers TMA proved to be useful and accurate in defining more favorable germinal center subtype of DLBCL from activated subtype by using only bcl6, CD10 and MUM1 antigens (4) .
Costs and quality control
Several technical issues apparently compensate for some loss of information due to the small tissue size. The staining of a single TMA slide provides a much greater degree of consistency and standardization than the immunostaining of hundreds of individual slides and reduces the amount of antibodies. This significantly reduces high variability of intralaboratory and interlaboratory results, mainly because of interlaboratory differences in antigen retrieval, staining protocols, antibodies used, and in the interpretation of staining results (5).
Furthermore, quantitation of immunostainings is markedly easier on arrayed samples than on large sections. Also, this facilitates a reproducible application of the selected scoring criteria because the entire tissue is always used for interpretation and the subjective selection of one tumor area for decision making is avoided. In the future, the TMA technology may 132 www.onk.ns.ac.yu/Archive December 15, 2005 help to optimize and standardize the interpretation of immunostainings, which is currently subjective and poorly reproducible and often leads to major discrepancies in studies investigating clinical associations for novel biomarkers (5).
Advantages and drawbacks of punches with varying diameter
A potential caveat of TM technology is the limited amount of tissue analyzed. The TMA approach has been criticized for its use of small punches of usually only 0.6 mm diameter from tumors with an original size of up to several centimeters in diameter, comprising areas of increased proliferation, apoptosis, matrix remodeling, necrosis, etc. The problem of tissue heterogeneity is maybe the most pronounced in lymphomas. Tumor cells, e.g. in Hodgkin's lymphoma or T-cell-rich B-cell lymphoma, are outnumbered by non-neoplastic background infiltrates and may only be present in very low numbers in TMA punch biopsies. In addition, lymphoma growth may follow lymphoid structures (such as follicles in FL or mantle zone infiltration in MCL), thus, TMA punch biopsies, in contrast to many solid tumors, may not contain relevant tumor areas. Furthermore, prognostic markers such as Ki67 or p53 are not homogeneously expressed, so that the lymphoma punch biopsy may not be representative of the whole neoplasm (6) (7) (8) . Several experimental and clinicopathological efforts has been made to reduce and even eliminate these concerns. In a recent paper of Hedavat and associates was clearly shown that TMA technique could be used reliably in lymphomas to characterize protein and mRNA expression level (9) . In spite of the drawbacks mentioned above, lymphomas can be reproducibly evaluated on TMA (9).
Nevertheless, criteria for evaluation of quantitatively expressed markers can strongly influence the rate of concordance. The facts that maximum expression of heterogeneously expressed markers cannot be reliably determined on TMA due to tissue heterogeneity and the limited amount of tissue in punch biopsies do not outweigh the enormous advantages of TMA, namely cost-and time-saving and the mostly homogeneous results of immunohistochemistry (9) . Of course it can not be overemphasized in this context that care in the composition of an array and a certain degree of redundancy is essential to minimize TMA sampling drawbacks, because the selection of different tumor areas should be oriented towards the requirements of the investigated tumor entity.
Among alternatives to circumvent these problems is the use of larger punch needles of up to 2 mm diameter. Nevertheless, for the use of TMA in cancer research, no obvious advantage can be seen, because when compared with the original size of a tumor with a diameter of up to several centimeters, an area of about 3 mm 2 (2 mm diameter) is hardly more "representative" than 0.27 mm 2 (0.6 mm diameter). In addition, the obvious disadvantage is that instead of several hundreds of tumors on a single slide/section, far fewer than 100 samples can be investigated at the same time. These large punches also cause considerable damage to the donor and acceptor block using conventional paraffin wax blocks.
Despite the fact that these arrays might be suboptimal for cancer research, large punch arrays may be preferable for distinct areas of research and perhaps routine practice. In our, study we used 2 mm punch needle. The number of core samples per case is also important issue. TMA immunostaining results agree with whole tissue section staining in 86% to 100% of cases and, as the number of core samples increases, the level of agreement also increases (10) . In lymphomas was found that added redundancy of 3 cores/case reduced the numbers of cases placed on TMA, but it did not increased the accuracy of a particular stain if tumor cells were present (9) . Moreover, in situations with careful core sampling especially in large studies, a single sample from each tumor may often be sufficient to derive information on clinical associations (5).
The aim of this study was to show diagnostic and prognostic significance of TMA based on the experience obtained from our patients.
PATIENTS AND METHODS
All patients with histological diagnosis of B cell non-Hodgkin's lymphoma according to updated Kiel classification criteria as well as those with immunophenotype were considered eligible. Patients diagnosed and treated at the clinic of Hematology and clinical immunology Clinical center Ni¹ between 1991 and 2002 were followed and clinically evaluated using the well established prognostic parameters. From the initial 169 patients biopsy material from only 65 patients were additionally analyzed.
Preparation of "donor" tissue microarray blocks
Areas containing the most characteristic features of pathologic process on hematoxylineosin (H&E) stained slides were identified and marked. After putting the marked slides over the surface of paraffin block, arras on the block corresponding to regions on the slide could be identified and marked.
Preparation of "recipient" tissue microarray block
Empty paraffin blocks (recipient block) 30 x 24 mm in diameter and 4 mm deep was prepared with standard mould placed on the standard holder. Block surface was divided on 45 squares (5 columns and 9 rows) by line drawn with marker. Modified kidney biopsy needle 2 mm thick was used to cut out 2 mm wax cylinders from the recipient block, creating 45 holes. Modification was done by cutting and flattening the tip of stylet of the needle.
Construction of the array
Marked region of the donor block was punched out with modified needle and small tissue cylinder was arrayed in to the recipient block. Tissue cylinder was pressed out of the needle gently in to the hole with modified stylet. Procedure has been done repeatedly until complete recipient block was filed. Each sample placed in to the recipient block had to be properly marked in the appropriate table. Recipient blocks ("microarray") were homogenized and embedded. Two such blocks were made. 
Microphotography
All H&E and immunohistochemistry images were analyzed using a Nikon Eclipse 600 microscope (Nikon, Burlingame, CA). Images were photographed with a Nikon DS5M digital camera in resolution 1260x980 pixels. Digitized images were processed using Adobe 
Statistical analysis
Kaplan-Meier method and log-rank test were used for calculating of survival and univariate differences between groups. P<0.05 was required for statistical significance. Cox regression analysis was used for multivariate analysis. For all calculations a two-sided tests were used.
RESULTS

Immunophenotyping of B cell Non Hodgkin's lymphoma using TMA
Diffuse large B cell lymphoma
Fourteen patients were completely analyzed and all of them were CD20 + , CD5 -, CD10 -, CD23 -, Oct2 + , BOB1 + , Cyclin D1 -, and CD138 -. Expression of Bcl2 and Bcl6 was recorded in 6/14 patients, CD43 and MUM1 in 2/14 and p53 in 7/14 patients. MUM1, Bcl6, CD10, and CD138 antigens were used for building and classifying patients according to defined DLBCL subtypes (11) with 5 germinative center type and 3 activated type DLBCL cases.
One patient was considered post-germinative center type displaying double positivity for MUM1 and Bcl6 according to criteria given by the same author. Remaining group was classified as complete negative group. Two patients were identified as T cell rich B cell lymphoma according to their morphology, and CD20 + , Oct2 and BOB1 positivity.
Kaplan Meier analysis showed better prognosis of patients with Bcl6 + immunophenotype comparing to Bcl6-cases (two year survival estimate was 19.8% vs. 0; log rank p=0.0447) (Figure 2 ).
Mantle cell lymphoma
Nine of twelve cases were classic while three were blastoid subtype of mantle cell lymphoma. All cases were CD20 + , CD5 + , Cyclin D1 + , CD3 -, Bcl2 + , Oct2 + , BOB1 + , Pax5 + , CD10 -, CD21 -, CD23 -, Bcl6 -. All cases of classic mantle cell lymphoma had Ki-67 proliferation index <10%, while in blastoid subtype all three had >60% Ki-67 + cells.
In 2/5 classic and in 2/3 blastoid cases nuclear P53 + was recorded. CD43 was absent in all classic cases while focal positivity was recorded in all blastoid specimens. In classic subtype, both MUM1 and CD138 could not be detected while MUM1 was present in 3/3 blastoid cases.
Indolent lymphomas
There were 14 cases of chronic lymphocytic leukemia/small cell lymphocytic lymphoma (CLL/SLL), 6 cases with follicular lymphoma (FL), 5 cases of marginal zone lymphoma (MZ), and 7 cases of lymphoplazmacitoid lymphoma (LP). Their immunophenotype was shown in Table 2 . In this heterogeneous group of patients Kaplan-Meier 4 year survival estimate in patients with p53 +/-was 25% while in p53 -group it was 80% (log rank p=0.0475) (Figure 3 ).
DISCUSSION
It is increasingly evident that molecular diagnostics, that is, the use of diagnostic testing to understand the molecular mechanisms of an individual patient's disease, will be pivotal in the delivery of safe and effective therapy for many diseases in the future. A huge body of new information on the genetic, genomic and proteomic profiles of different hematopoietic diseases is accumulating. In this study, we applied high-throughput TMA to study lymphomas and showed that this technique can be used as a reliable method in diagnosis and prognosis of hematological diseases.
In most cases expression of markers used in our study correlates with published results.
The characteristic immunophenotype of MCL (CD20 + , CD5 + , CyclinD1 + , CD10 -, CD23 -) was conserved in all cases. For markers such as MUM1 defining plasmacytic differentiation range we found positivity in 3/3 blastoid subtype of mantle cell lymphoma. There are no reports in literature concerning this finding to our knowledge. Association of MUM1 protein expression and poor prognosis in blastoid mantle cell lymphoma should be examined.
Expression of MUM1 is connected with constant activation of NFkB pathway and is already identified as adverse prognostic factor in CLL/SLL (12) and DLBCL(4). In our cohort of patients with CLL/SLL, MUM1 + on TMA could be easily detected as focal in 3/8 cases. In case of CD43 expression, wich does not neceserily define the disease class, but is reported to be positive in the majority of CLLSLLs and mantle cell lymphomas (13) we also found a high rate of positive cases.
Markers of proliferation such as Ki 67 have significant prognostic value in mantle cell lymphomas. Our patients with blastoid subtype had Ki 67 index over 60% on TMA. This is in agreement with Ratty and coworkers who found increased risk for transformation from classic to blastoid subtype with 25% of Ki-67 + tumor cells (8, 14) . This prognostic cut of point is compatible to results of gene expresion profilng analyzis of mantle cell lymphomas (15) .
In case of heterogeneous expression of markers such as KI-67 and p53 TMA could not be reliably assess the maximal expression. Nevertheless, in case of mean KI-67 and p53 expression, TMA showed 90 and 92% concordance rate with conventional tissue sections and that could be sufficient for routine practice (16) . In our cohort of indolent lymphoma, group and the fact that some molecular alterations appear to occur exclusively in this concrete subset may support the idea that this DLBCL subgroup actually represents a distinct entity with specific mechanisms of transformation. When TMA and quantitave whole tissue stainings were compared in DLBCL, concordance of 90% was obtained for Bcl6 (9, 22) .
Furthermore, bcl6, in conjunction with CD10 and MUM1, is a useful marker to identify the GCB phenotype. However, some cases of DLBCL that express bcl6 and MUM1 have an ABC gene expression pattern. The existence of a large group of double bcl6+ MUM1+ cases demonstrates that the mutual exclusion of these markers, as observed in reactive germinal centers, is not preserved in DLBCLs. We had one such case but there are reports with TMA immunophenotype reaching as high as 47% of DLBCL (22) . Although these cases express bcl6, the outcome is most likely to be that of the ABC subtype, and this may explain why there are discrepancies in outcome prediction when using bcl6 expression alone. The cases in some studies were investigated using a polyclonal anti-bcl6 antibody.
More recently, a monoclonal antibody (clone PG-B6p), which is also suitable for detection of the bcl6 molecule in routine biopsies, has become commercially available. The monoclonal antibody should facilitate future tissue microarray studies because of its high specificity, absence of background staining, and the good reproducibility of immunostaining results between different centers.
Besides high risk of background staining, TMA proved to be highly compatible with cDNA microarray. Using TMA, Hans and co workers showed that, CD10, Bcl6, and MUM1 can be combined to divide DLBCL into GCB and non-GCB subgroups with an outcome similar to It can be concluded that TMA methodology is highly advantageous in spite of its limitations.
This could be evidenced through the logarithmic increase of published papers in which TMA technology was used. The progress in gaining knowledge of the molecular biology of hematolymphoid neoplasms has been substantial, and TMA technology provides a valuable tool to accelerate this process.
